MCID: INH004
MIFTS: 41

Inherited Blood Coagulation Disease

Categories: Blood diseases

Aliases & Classifications for Inherited Blood Coagulation Disease

MalaCards integrated aliases for Inherited Blood Coagulation Disease:

Name: Inherited Blood Coagulation Disease 12 15
Blood Coagulation Disorders, Inherited 29 44

Classifications:



External Ids:

Disease Ontology 12 DOID:2214
MeSH 44 D025861
UMLS 73 C0852077

Summaries for Inherited Blood Coagulation Disease

MalaCards based summary : Inherited Blood Coagulation Disease, also known as blood coagulation disorders, inherited, is related to pseudo-von willebrand disease and antithrombin iii deficiency. An important gene associated with Inherited Blood Coagulation Disease is VWF (Von Willebrand Factor), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Collagen chain trimerization. The drugs Thrombin and Tranexamic Acid have been mentioned in the context of this disorder. Affiliated tissues include bone, testes and liver, and related phenotypes are cardiovascular system and hematopoietic system

Related Diseases for Inherited Blood Coagulation Disease

Diseases in the Blood Coagulation Disease family:

Inherited Blood Coagulation Disease

Diseases related to Inherited Blood Coagulation Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 157)
# Related Disease Score Top Affiliating Genes
1 pseudo-von willebrand disease 32.3 GP1BA VWF
2 antithrombin iii deficiency 31.7 F2 SERPINC1
3 bleeding disorder, platelet-type, 16 31.4 ITGA2B ITGB3
4 hemophilia b 29.6 F2 F3 F7 F8 F9 SERPINC1
5 bernard-soulier syndrome 27.5 F2 F8 GP1BA GP1BB GP9 ITGA2B
6 glanzmann thrombasthenia 26.9 F2 F3 F8 F9 GP1BA GP9
7 gray platelet syndrome 10.8
8 bleeding disorder, platelet-type, 17 10.8
9 scott syndrome 10.8
10 quebec platelet disorder 10.8
11 bleeding disorder, platelet-type, 12 10.8
12 platelet glycoprotein iv deficiency 10.8
13 bleeding disorder, platelet-type, 8 10.8
14 bleeding disorder, platelet-type, 14 10.8
15 bleeding disorder, platelet-type, 9 10.8
16 bleeding disorder, platelet-type, 11 10.8
17 bleeding disorder, platelet-type, 15 10.8
18 bleeding disorder, platelet-type, 18 10.8
19 bleeding disorder, platelet-type, 19 10.8
20 bleeding disorder, platelet-type, 20 10.8
21 fainting 10.8 F8 VWF
22 mild hemophilia a 10.8 F8 VWF
23 cerebral arteritis 10.8 F8 VWF
24 platelet aggregation, spontaneous 10.7 SERPINC1 VWF
25 congenital disorder of glycosylation, type ia 10.6 F9 SERPINC1
26 lymphangiosarcoma 10.6 F8 VWF
27 active peptic ulcer disease 10.6 F2 VWF
28 von willebrand disease, type 2 10.6 F7 F8 VWF
29 mesenteric vascular occlusion 10.5 F2 F7
30 spinal cord infarction 10.5 F2 SERPINC1
31 vitamin k deficiency hemorrhagic disease 10.5 F2 F8
32 blood protein disease 10.5 F2 SERPINC1
33 von willebrand disease, type 3 10.5 F8 GP1BA VWF
34 malignant skin fibrous histiocytoma 10.5 F7 F9 ITGA2B
35 alpha-2-plasmin inhibitor deficiency 10.5 F2 SERPINC1
36 malignant dermis tumor 10.5 F7 F9 ITGA2B
37 prothrombin deficiency, congenital 10.4 F2 SERPINC1
38 ischemic colitis 10.4 F2 SERPINC1
39 anterior spinal artery syndrome 10.4 F2 SERPINC1
40 subendocardial myocardial infarction 10.4 F2 SERPINC1
41 sneddon syndrome 10.4 F2 SERPINC1
42 basilar artery occlusion 10.4 F2 ITGA2B
43 esophageal varix 10.4 F2 SERPINC1
44 factor viii deficiency 10.4 F2 F8 VWF
45 cardiac tamponade 10.3 F2 F8 F9
46 ischemic heart disease 10.3 F2 F7
47 retinal vascular occlusion 10.3 F2 SERPINC1
48 heparin-induced thrombocytopenia 10.3 F3 SERPINC1
49 chronic thromboembolic pulmonary hypertension 10.3 F2 FGB
50 hemarthrosis 10.3 F7 F8 F9 VWF

Graphical network of the top 20 diseases related to Inherited Blood Coagulation Disease:



Diseases related to Inherited Blood Coagulation Disease

Symptoms & Phenotypes for Inherited Blood Coagulation Disease

MGI Mouse Phenotypes related to Inherited Blood Coagulation Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.91 SERPINC1 F3 VWF F7 F9 FGB
2 hematopoietic system MP:0005397 9.9 VWF F8 F9 GP1BA GP1BB GP9
3 homeostasis/metabolism MP:0005376 9.7 F3 VWF F7 F8 F9 GP1BA
4 immune system MP:0005387 9.23 SERPINC1 F3 VWF F8 F9 ITGA2B

Drugs & Therapeutics for Inherited Blood Coagulation Disease

Drugs for Inherited Blood Coagulation Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 206)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Thrombin Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1
2
Tranexamic Acid Approved Phase 4,Phase 3,Not Applicable 1197-18-8 5526
3
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 1 1994-09-7, 94-09-7 2337
4
Hyaluronic acid Approved, Vet_approved Phase 4,Not Applicable 9004-61-9 53477741
5
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
6
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
7
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
8
Ribavirin Approved Phase 4,Phase 1 36791-04-5 37542
9
Didanosine Approved Phase 4 69655-05-6 50599
10
Indinavir Approved Phase 4 150378-17-9 5362440
11
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
12
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
13
Zalcitabine Approved, Investigational Phase 4 7481-89-2 24066
14
Zidovudine Approved Phase 4,Phase 1,Not Applicable 30516-87-1 35370
15
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
16 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 1
17
Serine Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 56-45-1 5951
18 Coagulants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
19 Factor VIII Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 Hemostatics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Anti-Infective Agents Phase 4,Phase 2,Phase 1,Not Applicable
22 Antimetabolites Phase 4,Phase 1,Phase 2,Not Applicable
23 Antiviral Agents Phase 4,Phase 2,Phase 1,Not Applicable
24 Anti-HIV Agents Phase 4,Phase 2,Phase 1,Not Applicable
25 Anti-Retroviral Agents Phase 4,Phase 2,Phase 1,Not Applicable
26 Anticoagulants Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
27 Fibrinolytic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
28 Antibodies Phase 4,Phase 3,Phase 2,Phase 1
29 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1
30 Antibodies, Bispecific Phase 4,Phase 3,Phase 1
31 Antifibrinolytic Agents Phase 4,Phase 3,Not Applicable
32 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
33 Adjuvants, Immunologic Phase 4,Phase 2,Not Applicable
34 Hylan Phase 4
35 Protective Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
36 triamcinolone acetonide Phase 4
37 Triamcinolone diacetate Phase 4
38 Triamcinolone hexacetonide Phase 4
39 Viscosupplements Phase 4,Not Applicable
40 gamma-Globulins Phase 4,Phase 3
41 Immunoglobulins, Intravenous Phase 4,Phase 3
42 Rho(D) Immune Globulin Phase 4,Phase 3
43 Arginine Vasopressin Phase 4,Phase 2,Phase 1,Not Applicable
44 Deamino Arginine Vasopressin Phase 4,Phase 2,Phase 1,Not Applicable
45 Natriuretic Agents Phase 4,Phase 2,Phase 1,Not Applicable
46 Vasopressins Phase 4,Phase 2,Phase 1,Not Applicable
47 Interferon-alpha Phase 4
48 interferons Phase 4
49 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
50 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 637)
# Name Status NCT ID Phase Drugs
1 Subclinical Joint Bleeding in Irish Adults With Severe Haemophilia A on Personalised Prophylaxis Regimens Unknown status NCT02314325 Phase 4 ADVATE [Antihemophilic Factor (Recombinant)];ADVATE [Antihemophilic Factor (Recombinant)]
2 BAY14-2222 Prophylaxis and Joint Function Improvement (Adults) Completed NCT00586521 Phase 4 Kogenate (BAY14-2222)
3 Comparison of Different Prophylaxis Regimens for Moderate to Severe Hemophilia A Pediatric Patients Completed NCT02727647 Phase 4 FVIII;FVIII
4 Efficacy and Cost Effectiveness of Pharmacokinetic Dosing in Haemophilia A Completed NCT02697370 Phase 4 Pharmacokinetic based dosage change
5 PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A Completed NCT02492984 Phase 4 Intravenous infusions of Xyntha
6 China ADVATE PTP Study Completed NCT02170402 Phase 4
7 Prophylaxis Versus on Demand Treatment for Children With Hemophilia A Completed NCT01810666 Phase 4
8 Canadian Hemophilia Prophylaxis Study Completed NCT01085344 Phase 4
9 Survey of Inhibitors in Plasma-Product Exposed Toddlers Completed NCT01064284 Phase 4 PLASMA DERIVED Factor VIII;Recombinant FVIII
10 Study of Safety And Efficacy Of ReFacto AF In Previously Untreated Hemophilia A Patients In The Usual Care Setting Completed NCT00950170 Phase 4
11 Joint Status in Subjects With Severe Hemophilia A in Relation to Different Treatment Regimens Completed NCT00927667 Phase 4
12 Pharmacokinetic Study of ADVATE 3000 IU in Previously Treated Patients With Severe Hemophilia A Completed NCT00916032 Phase 4
13 Study Evaluating Safety And Efficacy Of Moroctocog Alfa (AF-CC) In Previously Treated Hemophilia A Patients Completed NCT00914459 Phase 4
14 Pharmacokinetic Comparison of Advate rAHF-PFM With Recombinate rAHF in Patients With Severe Hemophilia A Completed NCT00666406 Phase 4 Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method (rAHF-PFM);Recombinant Factor VIII (rAHF)
15 Russian Kogenate Pediatric Study Completed NCT00632814 Phase 4 rFVIII-FS (Kogenate FS, BAY14-2222) 70 IU/kg, dosing once per week;rFVIII-FS (Kogenate FS, BAY14-2222), 70 IU/kg twice per week (30 IU/kg + 40 IU/kg);rFVIII-FS (Kogenate FS, BAY14-2222) 75 IU/kg, dosing three times per week (3 x 25 IU/kg)
16 Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery Completed NCT00357656 Phase 4 Recombinant Protein-Free Factor VIII (rAHF-PFM);Recombinant Protein-Free Factor VIII (rAHF-PFM)
17 Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A Completed NCT00289536 Phase 4
18 Combination Therapy of Low Doses of rFVIIa and FEIBA for Severe Hemophilia A Patients With an Inhibitor to Factor VIII Completed NCT00284193 Phase 4 rFVIIa-FEIBA therapy for hemophilia A inhibitors;FEIBA- Activated Prothrombin Complexes
19 Prophylaxis Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A Completed NCT00243386 Phase 4 Antihemophilic factor, recombinant, manufactured protein-free;Antihemophilic factor, recombinant, manufactured protein-free
20 Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A Completed NCT00168051 Phase 4 ReFacto;Advante
21 Study Evaluating ReFacto® in Hemophilia A Undergoing Major Surgery Completed NCT00092976 Phase 4 ReFacto
22 Study of Voncento® in Subjects With Von Willebrand Disease Completed NCT02552576 Phase 4
23 Safety and Efficacy of Benefix in Patients With Hemophilia B in Usual Care Settings in China Completed NCT02336178 Phase 4 Benefix
24 A Comparison Study of Bypassing Agent Therapy With and Without Tranexamic Acid in Haemophilia A Patients With Inhibitor Completed NCT01800435 Phase 4 aPCC, aPCC + TXA;rFVIIa, rFVIIa + TXA
25 Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery Completed NCT01561391 Phase 4 activated recombinant human factor VII;activated recombinant human factor VII;factor VIII
26 IMMUNINE Pre-Treatment Study Completed NCT01128881 Phase 4
27 Study Evaluating BeneFIX in Patients With Haemophilia B, Previously Treated With Plasma Derived Factor IX Completed NCT00749476 Phase 4
28 Impact of Conservative Treatment by Custom-made Orthoses in Patients With Haemophilic Ankle Arthropathy Completed NCT00638001 Phase 4
29 Study Evaluating BENEFIX in Previously Treated Patients With Hemophilia B Completed NCT00581126 Phase 4 Recombinant Factor IX Coagulation
30 High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors Completed NCT00571584 Phase 4 activated recombinant human factor VII
31 Post Marketing Study in Haemophilia B Patients Using Nonafact® (Human Coagulation Factor IX) Completed NCT00139828 Phase 4 human coagulation Factor IX
32 Trial of NovoSeven® in Haemophilia - Joint Bleeds Completed NCT00108797 Phase 4 eptacog alfa (activated);Feiba VH
33 Viscosupplementation in Patients With Hemophilic Arthropathy Completed NCT01748201 Phase 4
34 A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency Completed NCT01289847 Phase 4
35 Severe Aortic Stenosis and Acquired Von Willebrand´s Disease: The Impact of Desmopressin in Valve-Replacement Surgery Completed NCT01994330 Phase 4 desmopressin
36 Pegasys® Plus Ribavirin in Hemophilic Patients With Hepatitis C Virus Infection Completed NCT00707772 Phase 4 PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin);PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)
37 Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD) Completed NCT00168090 Phase 4 Blood coagulation Factor VIII and vWF, human
38 Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia Completed NCT00002386 Phase 4 Indinavir sulfate;Lamivudine;Stavudine;Zidovudine;Zalcitabine;Didanosine
39 Exercise Versus DDAVP in Patients With Mild Hemophilia A Recruiting NCT03379974 Phase 4 DDAVP Inhalant Product
40 Study of Emicizumab Prophylaxis in Participants With Hemophilia A and Inhibitors Undergoing Minor Surgical Procedures Recruiting NCT03361137 Phase 4 Emicizumab
41 INdividualized ITI Based on Fviii(ATE) Protection by VWF Recruiting NCT03204539 Phase 4 Wilate
42 DDAVP vs. Exercise in Patients With Mild Hemophilia A Recruiting NCT03136003 Phase 4 DDAVP
43 Study of rFVIIIFc for ITI in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies Recruiting NCT03103542 Phase 4
44 A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study) Recruiting NCT03093480 Phase 4
45 A Clinical Phenotype Based Individualized Prophylaxis in Chinese Hemophilia A Children Recruiting NCT02999308 Phase 4
46 Safety/Efficacy Study to Assess Whether FVIII/VWF Concentrate Can Induce Immune Tolerance in Haemophilia A Patients Recruiting NCT02479087 Phase 4 Plasma-derived FVIII/VWF concentrate
47 Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A Recruiting NCT00323856 Phase 4 Alphanate SD/HT
48 Efficacy and Safety of Fanhdi®, a High-purity Von Willebrand Containing FVIII Concentrate, in Pediatric Patients With Von Willebrand Disease Recruiting NCT02472665 Phase 4 plasma-derived FVIII/VWF concentrate Fanhdi
49 Research Study to Look at Side Effects During Regular Injection With Factor VIII Medicine Named Turoctocog Alfa for a 8 Weeks Period Recruiting NCT03449342 Phase 4 turoctocog alfa
50 Human Fibrinogen Concentrate in Pediatric Cardiac Surgery Recruiting NCT02822599 Phase 4 RiaStAP;Saline

Search NIH Clinical Center for Inherited Blood Coagulation Disease

Cochrane evidence based reviews: blood coagulation disorders, inherited

Genetic Tests for Inherited Blood Coagulation Disease

Genetic tests related to Inherited Blood Coagulation Disease:

# Genetic test Affiliating Genes
1 Blood Coagulation Disorders, Inherited 29

Anatomical Context for Inherited Blood Coagulation Disease

MalaCards organs/tissues related to Inherited Blood Coagulation Disease:

41
Bone, Testes, Liver, Bone Marrow, Heart, Lung, Skin

Publications for Inherited Blood Coagulation Disease

Variations for Inherited Blood Coagulation Disease

Expression for Inherited Blood Coagulation Disease

Search GEO for disease gene expression data for Inherited Blood Coagulation Disease.

Pathways for Inherited Blood Coagulation Disease

Pathways related to Inherited Blood Coagulation Disease according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.85 F2 F3 F7 F8 F9 FGB
2
Show member pathways
12.76 F2 F3 F7 F8 F9 FGB
3
Show member pathways
12.15 FGB ITGA2B ITGB3 VWF
4
Show member pathways
12.12 FGB GP1BA GP1BB GP9 ITGA2B ITGB3
5 12.07 F2 F3 F7 F8 F9 FGB
6 12 FGB GP1BA GP1BB GP9 ITGA2B ITGB3
7
Show member pathways
11.96 FGB ITGA2B ITGB3 VWF
8 11.86 GP1BA GP1BB GP9 ITGA2B ITGB3
9 11.82 GP1BA ITGA2B ITGB3
10
Show member pathways
11.78 F2 F7 F9
11
Show member pathways
11.75 F2 FGB GP1BA GP1BB GP9 ITGA2B
12 11.68 F3 ITGB3 VWF
13
Show member pathways
11.57 F2 F3 F7 F8 F9 FGB
14 11.51 F2 FGB GP1BB GP9 ITGA2B ITGB3
15 11.39 GP9 ITGA2B ITGB3
16 11.13 ITGA2B ITGB3
17 11.02 ITGA2B ITGB3
18 10.91 ITGA2B ITGB3
19 10.87 GP1BA GP1BB GP9 VWF
20 10.86 F2 F7 F9
21 10.73 GP1BA GP1BB GP9 VWF

GO Terms for Inherited Blood Coagulation Disease

Cellular components related to Inherited Blood Coagulation Disease according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.91 F2 F3 F9 FGB GP1BA ITGA2B
2 cell surface GO:0009986 9.83 F3 FGB GP1BA ITGA2B ITGB3
3 Golgi lumen GO:0005796 9.65 F2 F7 F9
4 blood microparticle GO:0072562 9.62 F2 FGB ITGA2B SERPINC1
5 platelet alpha granule lumen GO:0031093 9.54 F8 FGB VWF
6 integrin complex GO:0008305 9.52 ITGA2B ITGB3
7 platelet alpha granule membrane GO:0031092 9.51 ITGA2B ITGB3
8 platelet alpha granule GO:0031091 9.49 FGB VWF
9 plasma membrane GO:0005886 9.4 F2 F3 F7 F8 F9 FGB
10 endoplasmic reticulum lumen GO:0005788 9.35 F2 F7 F8 F9 SERPINC1
11 serine-type peptidase complex GO:1905286 9.16 F3 F7
12 extracellular region GO:0005576 10.01 F2 F3 F7 F8 F9 FGB
13 extracellular space GO:0005615 10 F2 F3 F7 F8 F9 FGB

Biological processes related to Inherited Blood Coagulation Disease according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 cell adhesion GO:0007155 9.99 GP1BA GP1BB GP9 ITGA2B ITGB3 VWF
2 blood coagulation GO:0007596 9.93 F2 F3 F7 F8 F9 FGB
3 platelet activation GO:0030168 9.86 F2 F8 FGB GP1BA GP1BB GP9
4 extracellular matrix organization GO:0030198 9.85 FGB ITGA2B ITGB3 VWF
5 ER to Golgi vesicle-mediated transport GO:0006888 9.84 F2 F7 F8 F9
6 platelet degranulation GO:0002576 9.77 F8 FGB ITGA2B ITGB3 VWF
7 cell-matrix adhesion GO:0007160 9.73 FGB ITGA2B ITGB3
8 platelet aggregation GO:0070527 9.71 FGB GP1BA ITGA2B ITGB3
9 hemostasis GO:0007599 9.7 F2 F3 F7 F8 F9 FGB
10 signal peptide processing GO:0006465 9.67 F2 F7 F9
11 fibrinolysis GO:0042730 9.65 F2 FGB GP1BA
12 regulation of blood coagulation GO:0030193 9.63 F2 GP1BA SERPINC1
13 peptidyl-glutamic acid carboxylation GO:0017187 9.61 F2 F7 F9
14 cell-substrate adhesion GO:0031589 9.58 ITGB3 VWF
15 positive regulation of blood coagulation GO:0030194 9.58 F2 F7
16 positive regulation of positive chemotaxis GO:0050927 9.57 F3 F7
17 positive regulation of platelet-derived growth factor receptor signaling pathway GO:0010641 9.52 F3 F7
18 blood coagulation, extrinsic pathway GO:0007598 9.5 F3 F7 F9
19 blood coagulation, intrinsic pathway GO:0007597 9.17 F2 F8 F9 GP1BA GP1BB GP9

Molecular functions related to Inherited Blood Coagulation Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.97 F2 F3 F7 F8 F9 FGB
2 identical protein binding GO:0042802 9.77 GP1BB ITGA2B ITGB3 SERPINC1 VWF
3 serine-type peptidase activity GO:0008236 9.43 F2 F7 F9
4 extracellular matrix binding GO:0050840 9.32 ITGA2B ITGB3
5 serine-type endopeptidase activity GO:0004252 9.26 F2 F3 F7 F9
6 protease binding GO:0002020 8.92 F3 ITGB3 SERPINC1 VWF

Sources for Inherited Blood Coagulation Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....